In Vitro Activity of APX2041, a New Gwt1 Inhibitor, and In Vivo Efficacy of the Prodrug APX2104 against Aspergillus fumigatus.
Publication
, Journal Article
Shaheen, SK; Juvvadi, PR; Allen, J; Shwab, EK; Cole, DC; Asfaw, YG; Kapoor, M; Shaw, KJ; Steinbach, WJ
Published in: Antimicrobial agents and chemotherapy
September 2021
Invasive aspergillosis (IA) due to Aspergillus fumigatus is a deadly infection for which new antifungal therapies are needed. Here, we demonstrate the efficacy of a Gwt1 inhibitor, APX2041, and its prodrug, APX2104, against A. fumigatus. The wild-type, azole-resistant, and echinocandin-resistant A. fumigatus strains were equally susceptible to APX2041 in vitro. APX2104 treatment in vivo significantly prolonged survival of neutropenic mice challenged with the wild-type and azole-resistant strains, revealing APX2104 as a potentially promising therapeutic against IA.
Published In
Antimicrobial agents and chemotherapy
DOI
EISSN
1098-6596
ISSN
0066-4804
Publication Date
September 2021
Volume
65
Issue
10
Start / End Page
e0068221
Related Subject Headings
- Prodrugs
- Microbiology
- Microbial Sensitivity Tests
- Mice
- Isoxazoles
- Drug Resistance, Fungal
- Aspergillus fumigatus
- Antifungal Agents
- Animals
- 3214 Pharmacology and pharmaceutical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Shaheen, S. K., Juvvadi, P. R., Allen, J., Shwab, E. K., Cole, D. C., Asfaw, Y. G., … Steinbach, W. J. (2021). In Vitro Activity of APX2041, a New Gwt1 Inhibitor, and In Vivo Efficacy of the Prodrug APX2104 against Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 65(10), e0068221. https://doi.org/10.1128/aac.00682-21
Shaheen, Shareef K., Praveen R. Juvvadi, John Allen, E Keats Shwab, D Christopher Cole, Yohannes G. Asfaw, Mili Kapoor, Karen Joy Shaw, and William J. Steinbach. “In Vitro Activity of APX2041, a New Gwt1 Inhibitor, and In Vivo Efficacy of the Prodrug APX2104 against Aspergillus fumigatus.” Antimicrobial Agents and Chemotherapy 65, no. 10 (September 2021): e0068221. https://doi.org/10.1128/aac.00682-21.
Shaheen SK, Juvvadi PR, Allen J, Shwab EK, Cole DC, Asfaw YG, et al. In Vitro Activity of APX2041, a New Gwt1 Inhibitor, and In Vivo Efficacy of the Prodrug APX2104 against Aspergillus fumigatus. Antimicrobial agents and chemotherapy. 2021 Sep;65(10):e0068221.
Shaheen, Shareef K., et al. “In Vitro Activity of APX2041, a New Gwt1 Inhibitor, and In Vivo Efficacy of the Prodrug APX2104 against Aspergillus fumigatus.” Antimicrobial Agents and Chemotherapy, vol. 65, no. 10, Sept. 2021, p. e0068221. Epmc, doi:10.1128/aac.00682-21.
Shaheen SK, Juvvadi PR, Allen J, Shwab EK, Cole DC, Asfaw YG, Kapoor M, Shaw KJ, Steinbach WJ. In Vitro Activity of APX2041, a New Gwt1 Inhibitor, and In Vivo Efficacy of the Prodrug APX2104 against Aspergillus fumigatus. Antimicrobial agents and chemotherapy. 2021 Sep;65(10):e0068221.
Published In
Antimicrobial agents and chemotherapy
DOI
EISSN
1098-6596
ISSN
0066-4804
Publication Date
September 2021
Volume
65
Issue
10
Start / End Page
e0068221
Related Subject Headings
- Prodrugs
- Microbiology
- Microbial Sensitivity Tests
- Mice
- Isoxazoles
- Drug Resistance, Fungal
- Aspergillus fumigatus
- Antifungal Agents
- Animals
- 3214 Pharmacology and pharmaceutical sciences